Clinical trial NCT04459117: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
Official title: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Patency of the Ductus Arteriosus
Acetaminophen
Extreme Prematurity
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
Collaborators: name: UPCET
name: PARTNERS for International clinical Research
name: Connect for Children
name: Global Foundation for the Care of Newborn Infants
First posted: 2020-07-07
Enrollment: 804
Sex: ALL
Minimum age (years): 23
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase II is a dose finding phase Phase III is a randomized, multicenter, double-blind, placebo-controlled superiority trial, two arms in a 1:1 ratio, evaluating an increasing of 10% of the percentage of survival without severe morbidity at 36 weeks of post menstrual age
Primary purpose: TREATMENT

Brief summary: TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth.

The Phase II is a dose finding phase in order to assess the minimum effective dose regimen of acetaminophen for the closure of PDA for neonates with a gestational age less than 27 weeks This part of the study will be conducted in 11 NICUs, in 4 countries (France, UK, Finland and Denmark).

The Phase III is The phase III is a randomized, multicenter, double-blind, placebo-controlled superiority trial, two arms in a 1:1 ratio, evaluating an increasing of 10% of the percentage of survival without severe morbidity at 36 weeks of post menstrual age. In the intervention arm, 20 mg/kg followed by 7.5 mg/kg quarter in die (QID) will be administered to the 27-28 weeks gestational age group (dosage confirmed through PK/PD data analysis from the previous Finnian study) and the dosage selected after the conclusion of the Phase II will be administered to the 23-26 weeks gestational age group. A group sequential design, with a total of 3 analyses (2 interim analyses and a final) and the O'Brien-Fleming alpha spending function is chosen for the trial. At the same time, a Bayesian sequential analysis is planned for safety endpoints

Detailed description: The Phase II will be conducted in 11 NICUs, in 4 countries (France, UK, Finland and Denmark). The estimated recruitment period is 6 months to enroll 30 preterm infants of 23-26 weeks of gestation. Four different loading/maintenance doses will be tested. The first level will be 20 mg/kg followed by 7.5 mg/kg quarter in die (QID) which correspond to the dosage selected for neonates with a PMA ≥27 weeks in the phase III according to data from Finland (Härkin, J Pediatr. 2016). The 2nd, 3rd and 4th level doses will stand for 25%, 50%, and 75% increase of the first level:

* 20 mg/kg loading dose then 7.5 mg/kg/6hours during 5 days (total = 20 doses)
* 25 mg/kg loading dose then 10 mg/kg/6hours during 5 days (total = 20 doses)
* 30 mg/kg loading dose then 12 mg/kg/6hours during 5 days (total = 20 doses)
* 35 mg/kg loading dose then 15 mg/kg/6hours during 5 days (total = 20 doses)

The first cohort of patients will be treated at the lowest starting dose level. Both, the Data Safety Monitoring Board (DSMB) and the statistician will be informed about the therapeutic response observed and the safety of treatment. The statistician will use these data for re-estimation of the posterior probability of success. The DSMB will be then informed about the statistical recommendation for the next dose level to use in the next cohort of 3 patients. The decision to go up, go down or stay on the same dose level will remain to the DSMB who will be free to follow or not the statistical recommendation. Dose escalation will not increase by more than one level, although dose de-escalations could be large.

At inclusion, basic data (pregnancy, blood results, birth and transfer) are recorded. After inclusion, systemic arterial pressure is measured before administration of the first dose of acetaminophen. Then the preterm infant receives a loading dose of acetaminophen. A first blood sample is collected just after end of loading dose infusion (T15min) to analyze Acetaminophen plasma level (0.2mL) ans ALT/AST (0.1ml to 0.3ml, according to local biological laboratory). Each 6 hours during the first 5 days of life, each preterm infant receives a perfusion of acetaminophen, so 20 doses are administered in total. Systemic arterial pressure is measured at 30', 60', 90', 120' after each dose. Each day, a cardiac echography is performed. After Dose 10, a second blood sample (0.3 ml to 0.5 ml according to local biological laboratory) is collected to analyze acetaminophen plasma level and ALAT \& ASAT.

During visit 1 at day 3, eCRF is completed for period Day 1 to Day 3. A few "bottom of blood tubes" sampled for routine care will be kept for others acetaminophen plasma level analysis. This will be done in centres where this procedure is possible.After the last dose of acetaminophen, a blood sample of 0,3 to 0.5ml (ideally 6 hours after the start of last infusion) is collected to analyze ALAT \& ASAT and Acetaminophen plasma level (0.2 ml).

During visit 2 at Day 5, eCRF is completed for period Day 4 to Day 5. A cardiac echography is performed after the last dose of acetaminophen. Data from a cerebral echography performed in routine care during the first week after the first dose will be recorded.

During Visit 3, at Day 7, CRF is completed, and the information about primary outcome (closure or not of the Ductus Arterosus) is sent by email to experts of the research unit EA 7323 " Evaluation of Therapeutics and pharmacology in perinatality and pediatrics ", University of Paris-Descartes, Paris, France.

The Phase III is a pragmatic trial. At inclusion, basic data (pregnancy, blood results, birth and transfert) are recorded. After inclusion, randomization is performed. After randomization, each infant receives a loading dose of acetaminophen or placebo before 12 hours of life. After the loading dose of Acetaminophen, a supplement of 0.1 to 0.3 ml of blood will be collected, as supplement of a blood sample performed in routine care for AST/ALT analysis. Each 6 hours during the first 5 days of life, each preterm infant receives a perfusion of placebo or acetaminophen, so 20 doses are administered in total. After the dose 10 of Acetaminophen, a supplement of 0.1 to 0.3 ml of blood will be collected as supplement of a blood sample performed in routine care for AST/ALT analysis. Few "bottom of blood tubes" sampled for routine care will be kept for acetaminophen plasma level analysis in 50 first preterm infants (25 in each gestational age group) chosen hospitalized in the NICUs participating to Phase II. This will be done in NICUs where this procedure is possible).

During visit 1 at Day 7, data describing baby care are recording day by day from Day 0 to Day 7. Around Day 7 (between Day6 and Day 10) one cardiac echography is performed.

During visit 2 at Day 28, a review of different cares received by the baby between Day 8 and Day 28 is recorded. Data from a cerebral echography performed in routine care, before 36 weeks of postmenstrual age or before discharge if it occurs before will be recorded in the eCRF. Result of the last ophthalmological examination performed in routine care before 36 weeks of postmenstrual age or before discharge if it occurs before, should be noted in the eCRF.

During visit 3 at 36 weeks of postmenstrual age or at first discharge home, whatever comes first, a review of mobidity (BPD, cerebral lesions, retinopathy, necrotizing enterocolitis) is performed to complete the primary endpoint. At the end of hospitalization, clinical data at discharge are recorded

Eligibility criteria: Inclusion Criteria:

* Birth between 23-26 W for Phase II, between 23-28 W for Phase III
* Post natal age \< 12 hours
* Parental or Legal Authority Consent
* Parents with a social security or health insurance (if applicable according to the local regulation)

Exclusion Criteria:

* Birth defect / Congenital anomaly
* Twin-to-twin transfusion syndrome not cured
* Suspicion of pulmonary hypoplasia
* Suspicion of hepatic impairment (hemorrhagic syndrome and/or severe hypoglycemia)
* Clinical instability that can lead to rapid death
* Impossibility to start treatment before 12 hours of life
* Parents placed under judicial protection
* Participation in other clinical trial using acetaminophen during the first 5 days of life, indomethacin or ibuprofen during the first 3 days of life or using rescue treatment of PDA not recommended in the TREOCAPA trial

Primary outcomes:
measure: Closure of Ductus Arteriosus (Primary endpoint of phase II)
timeFrame: Day 7
measure: The survival without severe morbidity (Primary endpoint of phase III)
timeFrame: Up to 36 weeks of post menstrual age
Secondary outcomes:
measure: Analgesia/sedation drugs consumption during first week after birth (Secondary endpoint of phase III)
timeFrame: Day 7
measure: Closure of Ductus arteriosus (Secondary endpoint of phase III)
timeFrame: Day 7
measure: Number of back-up treatment of PDA (Secondary endpoint of phase III)
timeFrame: At 36 weeks of Post menstrual age
measure: Number of days during the first week after birth with catecholamines administration (Secondary endpoint of phase III)
timeFrame: Day 7
measure: Early pulmonary hemorrhage (Secondary endpoint of phase III)
timeFrame: Day 7
measure: Blood acetaminophen levels in extrem preterm infant (Secondary endpoint of Phase II and Phase III)
timeFrame: Day 7
measure: Toxicity of Acetaminophen in extrem preterm infant (Secondary endpoint of Phase II and Phase III)
timeFrame: Day 7
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: Centre Hospitalier Universitaire de Liège
city: Copenhagen
country: Denmark
facility: The Juliane Marie Centre, Rigshospitalet, Copenhagen University hospital
city: Tallinn
country: Estonia
facility: East Tallinn Central Hospital
city: Tallinn
country: Estonia
facility: Tallinn Children's Hospital
city: Tartu
country: Estonia
facility: Tartu University Hospital, Neonatal and Paediatric Intensive Care Unit
city: Helsinki
country: Finland
facility: Helsinki University Hospital, Department of Children and Adolecents, Neonatology
city: Kuopio
country: Finland
facility: Kuopio University Hospital, Department of Pediatrics
city: Oulu
country: Finland
facility: Oulu University Hospital, Department of Pediatrics
city: Tampere
country: Finland
facility: Tampere University Hospital, Department of Pediatrics
city: Turku
country: Finland
facility: Turku University Hospital, Department of Peadiatrics
city: Angers
country: France
facility: CHU Angers
city: Lille
country: France
facility: Hopital Jeanne de Flandre
city: Lyon
country: France
facility: Hôpital Croix-Rousse
city: Lyon
country: France
facility: Hospice civils de Lyon, Hopital Femme Enfant
city: Marseille
country: France
facility: Hôpital Marseille Nord
city: Marseille
country: France
facility: Hôpital de la conception
city: Montpellier
country: France
facility: Hôpital Arnaud de Villeneuve, Département de Pédiatrie Néonatale et Réanimation Pédiatrique
city: Nantes
country: France
facility: CHU Nantes, Hopital mére Enfant
city: Paris
country: France
facility: Hôpital Necker - Enfants malades
city: Paris
country: France
facility: CENTRE hospitalier intercommunal de Creteil
city: Paris
country: France
facility: Hopital Cochin, Service de Médecine et Réanimation néonatales de Port-Royal
city: Paris
country: France
facility: Hopital Robert Debré, Néonatologie
city: Rennes
country: France
facility: CHU Rennes, Hopital Sud
city: Strasbourg
country: France
facility: CHU Strasbourg, Hôpital de Hautepierre
city: Toulouse
country: France
facility: Centre Hospitalo-Universitaire de Toulouse
city: Tours
country: France
facility: CHRU de Tours
city: Kecskemét
country: Hungary
facility: Bács Kiskun COUNTY HOSPITAL
city: Cork
country: Ireland
facility: Cork University Hospital
city: Ancona
country: Italy
facility: Azienda Ospedaliero - Universitaria delle Marche
city: Oslo
country: Norway
facility: Oslo University Hospital
city: Lisboa
country: Portugal
facility: Centro Hospitalar Universitário Lisboa Norte, EPE -Hospital Santa Maria
city: Porto
country: Portugal
facility: Centro Hospitalar e Universitário do Porto, EPE - Centro Materno Infantil do Norte
city: Solna
country: Sweden
facility: Karolinska University Hospital
city: Geneva
country: Switzerland
facility: Hopital Universitaire de Geneve (HUG) - Hopital des enfants
city: Lausanne
country: Switzerland
facility: University Children's Hospital Lausanne
city: Zürich
country: Switzerland
facility: University Hospital of Zürich
Study officials:
References: